Opthea to Participate in November Investor Conferences

Virtual Bell Potter Healthcare Conference, November 18, 2024

Jefferies London Healthcare Conference, November 19, 2024

MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.

Conference details are as follows:

Bell Potter Healthcare Conference
Presentation:	Monday, November 18, 2024, 3:00 PM AEDT (Virtual)
Presenter:	Frederic Guerard, PharmD, CEO, Opthea
The webcast will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.

Jefferies London Healthcare Conference 2024
One-on-One Meetings:	Tuesday, November 19, 2024
Participant:	Frederic Guerard, PharmD, CEO, Opthea

About Opthea

Opthea (ASX/NASDAQ: OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries

PJ Kelleher
LifeSci Advisors, LLC
Email: [email protected]
Phone: 617-430-7579

Media Inquiries

Silvana Guerci-Lena
NorthStream Global Partners
Email: [email protected]

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: [email protected] Web: www.opthea.com

Source: Opthea Limited

Source: Opthea Limited

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Globalstar Confirms Successful Launch of All 8 HIBLEO-4 Replacement Satellites
• The World's Leading Cause of Death Is Finally Becoming a Global Conversation. AnginaX Is Helping Build What Comes Next
• Best Memecoin Presale August 2026: Whales Are Secretly Accumulating These 5 Crypto Presales